VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
Has the Bubble Burst for Viking Therapeutics Stock?
The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors may have been hoping that another, larger healthcare company would acquire ...
The Pharma Letter15h
Viking sails ahead with pivotal trial and billion dollar cash pile
San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...
Viking Therapeutics price target raised to $125 from $122 at Raymond James
Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX) to $125 from $122 and keeps a Strong Buy ...
Hosted on MSN15h
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials
Viking Therapeutics ( VKTX, Financials) reported its fourth-quarter and full-year 2024 financial results, highlighting ...
Q4 2024 Viking Therapeutics Inc Earnings Call
Stephanie Diaz; Investor Relations Manager; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante; C ...